We use CRISPR to make precision cuts into a cell's genome and then use our patent-pending plasmid system to insert new genes into the cell. This produces a genetically-altered cell line for research use.
Our first product line is designed to help researchers visualize proteins and organelles inside the cell. By inserting genes that produce bioluminescent and fluorescent proteins, ExpessCells provides insight that enhances researchers' work.
Our novel technology allows ExpressCells to create custom cell lines in as few as 30 days. We can insert up to three genes in cells that continue to thrive and divide. We plan to launch commercial operations midyear 2019.
ExpressCells has completed the first close of its Series A financing round. The Rowan Innovation Venture Fund and Keiretsu Forum Mid-Atlantic are jointly leading this round. ExpressCells plans to use the $800,000 in proceeds from the first close of its Series A financing to build the commercial and operational infrastructure to sell its knock-in cell lines. This includes operating its lab in Philadelphia and establishing its promotional platform.
ExpressCells CEO Matt Handel was a guest on the Comcast show Money Matters. Watch the video to learn more about ExpressCells and the life of an entrepreneur.
ExpressCells presented to the Angel Capital Association as part of the Innovation Showcase. The company made connections to many leading angel investment groups.
ExpressCells presented to one of the leading entrepreneurial showcases in the area.
Serial entrepreneur with over 25 years experience in life sciences. Graduate of Princeton and the MIT Sloan School of Management. Launched multiple successful products. Worked in product development, business development, strategy, and commercial at both Merck and Shire.
Assistant Professor at Temple University School of Pharmacy. Conducts research on biochemistry and molecular biology. Inventor on multiple patents, including ExpressCells’ technology. Holds both medical and business degrees.
Former Managing Director of Catalysis Partners and president of The Exeter Group. Sold into most major pharma and biotech companies. Board-certified internist, attended Yale, received medical degree from NYU, and earned his business degree from the MIT Sloan School of Management.
Principal of CD Advisory Services, LLC, serving startups and development companies in life science. Worked with SaaS and consultancy firms, IT customized technology management, and biotech development companies including Shire. Graduated from Immaculata College and earned her MBA at Penn State.